Park, C.-K.; Jeon, N.; Park, H.-K.; Oh, H.-J.; Kim, Y.-C.; Jeon, H.-L.; Kim, Y.-H.; Ahn, S.-J.; Oh, I.-J.
A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer. Cancers 2023, 15, 1606.
https://doi.org/10.3390/cancers15051606
AMA Style
Park C-K, Jeon N, Park H-K, Oh H-J, Kim Y-C, Jeon H-L, Kim Y-H, Ahn S-J, Oh I-J.
A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer. Cancers. 2023; 15(5):1606.
https://doi.org/10.3390/cancers15051606
Chicago/Turabian Style
Park, Cheol-Kyu, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, and In-Jae Oh.
2023. "A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer" Cancers 15, no. 5: 1606.
https://doi.org/10.3390/cancers15051606
APA Style
Park, C.-K., Jeon, N., Park, H.-K., Oh, H.-J., Kim, Y.-C., Jeon, H.-L., Kim, Y.-H., Ahn, S.-J., & Oh, I.-J.
(2023). A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer. Cancers, 15(5), 1606.
https://doi.org/10.3390/cancers15051606
